Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Milton Packer(Baylor University Medical Center), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(London School of Hygiene & Tropical Medicine), James L. Januzzi(Harvard University), Matthias Zwick(Boehringer Ingelheim (Germany)), Maral Saadati(Boehringer Ingelheim (Germany)), Naveed Sattar(University of Glasgow), João Pedro Ferreira(Inserm), Mikhail Sumin(Boehringer Ingelheim (Germany)), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Javed Butler(Jackson Memorial Hospital)
Cited by 209
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k